Be the first to like.

Share

Although much of the focus has been on the amyloid hypothesis at the heart of that work — and other failed treatments — I believe we are overlooking another key driver for numerous translational failures: the overreliance on behavioral readouts from contrived transgenic rodent models to guide drug development for Alzheimer’s, Parkinson’s, and other neurologic diseases. We need to find ways to move beyond this flawed paradigm.

The Food and Drug Administration has put in place well-established guidelines for preclinical safety studies. But the FDA does not typically weigh in on preclinical effectiveness studies. It’s generally up to individual companies to decide when an investigational compound has shown enough potential to merit advancing it into high-risk and high-cost clinical trials.

…continue reading ‘The Trouble With Mice As Behavioral Models for Alzheimer’s and Other Neurologic Diseases’

Image via Flickr AttributionNoncommercialNo Derivative Works Some rights reserved by Rick Eh?

Be the first to like.

Share
STAT

Tags: , , , , , , , , , ,

Leave a Reply